Study guide
7.3 Muscle, NMJ & Peripheral Nerve Disorders
NBME Comprehensive Basic Science Examination CBSE
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Navigation
1.1 Current Exam Facts & Administration 1.2 Content Blueprint & Physician Tasks 1.3 Scoring, Score Reports & Step 1 Readiness
2 Human Development
2.1 Embryology & Congenital Development Patterns 2.2 Normal Age-Related Findings & Well-Patient Care
3 Blood & Hematologic Disease
3.1 Hematopoiesis, RBC Disorders & Anemias 3.2 Hemostasis, Thrombosis & Coagulopathies 3.3 WBC Disorders, Leukemia & Lymphoma Mechanisms
4 Immune System
4.1 Innate & Adaptive Immunity Mechanisms 4.2 Hypersensitivity, Autoimmunity & Immunodeficiency 4.3 Transplant Immunology & Immune Pharmacology
5 Nervous System Anatomy & Disease
5.1 Neuroanatomy Localization & Pathways 5.2 Stroke, Infection, Demyelination & Trauma 5.3 Seizures, Movement Disorders & Neurodegeneration 5.4 Special Senses: Eye & Ear Mechanisms
6 Behavioral Health
6.1 Psychiatric Disorders & Diagnostic Patterns 6.2 Psychopharmacology Mechanisms 6.3 Neurotransmitters, Learning & Behavioral Science
7 Musculoskeletal System
7.1 Bone Physiology, Fracture Healing & Bone Pathology 7.2 Joint Disease, Rheumatology & Connective Tissue 7.3 Muscle, NMJ & Peripheral Nerve Disorders
8 Skin & Soft Tissue
8.1 Dermatopathology High-Yield Lesions 8.2 Inflammation, Wound Healing & Soft-Tissue Infection
9 Cardiovascular Pathophysiology
9.1 Cardiac Cycle, Hemodynamics & Murmurs 9.2 Ischemic Heart Disease & Cardiomyopathy 9.3 Congenital & Valvular Heart Disease 9.4 Vascular Pathology & Hypertension
10 Cardiovascular Pharmacology
10.1 Antihypertensives, Heart Failure & Antiarrhythmics 10.2 Antiplatelets, Anticoagulants & Lipid Drugs
11 Respiratory System
11.1 Pulmonary Mechanics & Gas Exchange 11.2 Obstructive, Restrictive & Vascular Lung Disease 11.3 Pulmonary Infections, Neoplasms & Respiratory Pharmacology
12 Renal Physiology & Electrolytes
12.1 Nephron Transport & Renal Physiology 12.2 Electrolyte Disorders 12.3 Acid-Base Physiology & Compensation
13 Renal Pathology
13.1 Glomerular Disease Mechanisms 13.2 Tubulointerstitial, Vascular & Stone Disease
14 Gastrointestinal System
14.1 GI Physiology, Motility & Digestion 14.2 Esophagus, Stomach & Intestinal Pathology 14.3 Liver, Biliary Tree & Pancreas 14.4 GI Microbiology, Nutrition & Malabsorption
15 Endocrine System
15.1 Hormone Signaling & Hypothalamic-Pituitary Axes 15.2 Thyroid & Parathyroid Disease 15.3 Adrenal Disorders & Steroid Pharmacology 15.4 Diabetes, Glucose Homeostasis & Metabolic Syndrome
16 Reproductive System
16.1 Male & Female Reproductive Physiology 16.2 Pregnancy, Placenta & Developmental Toxicology 16.3 Reproductive Pathology & Hormone-Related Neoplasia
17 Multisystem Processes & Disorders
17.1 Cell Injury, Inflammation & Repair 17.2 Neoplasia Principles & Tumor Biology 17.3 Infection, Sepsis & Multisystem Microbial Disease 17.4 Genetics, Inborn Errors & Environmental Toxicology
18 Biostatistics & Epidemiology
18.1 Study Design, Bias & Causation 18.2 Diagnostic Test Metrics & Screening 18.3 Epidemiology Measures & Population Health
19 Social Sciences & Communication
19.1 Ethics Principles & Decision-Making Capacity 19.2 Communication Skills & Difficult Conversations 19.3 Professionalism, Systems & Practice-Based Learning
20 Integrated Disciplines Capstone
20.1 High-Yield Microbiology Anchors Across Systems 20.2 High-Yield Biochemistry & Molecular Mechanisms 20.3 Integrated Pharmacology Strategy & Exam-Day Execution
7.3 Muscle, NMJ & Peripheral Nerve Disorders
Key Takeaways Explain This Topic AI
Skeletal muscle excitation–contraction couples T-tubule depolarization to SR calcium release via DHPR–ryanodine receptor interaction; Ca²⁺–troponin enables actin–myosin cross-bridges.
Type I fibers are slow oxidative and fatigue-resistant; Type II fibers are fast, with IIA intermediate oxidative capacity and IIX/IIB more glycolytic and fatigable.
Duchenne (frameshift, absent dystrophin) is earlier/severe versus Becker (in-frame, reduced dystrophin); myotonic dystrophy is CTG repeat disease with grip myotonia and systemic features.
MG is postsynaptic AChR (or MuSK) antibody disease with fatigable weakness improving with acetylcholinesterase inhibition conceptually; LEMS is presynaptic VGCC antibodies with autonomic features and cancer association.
Neuropathies split demyelinating (slowed conduction, often areflexia early) versus axonal; GBS is acute post-infectious polyradiculoneuropathy, whereas CIDP is the chronic immune-mediated counterpart.
Last updated: August 2026
Skeletal Muscle Excitation–Contraction Coupling
A motor neuron action potential invades the presynaptic terminal, opens voltage-gated Ca²⁺ channels (P/Q-type VGCC) , and triggers acetylcholine (ACh) vesicle release into the synaptic cleft. ACh binds nicotinic ACh receptors on the motor end plate, opening cation channels → end-plate potential → muscle action potential if threshold is reached. The muscle AP propagates along the sarcolemma and into T-tubules . Voltage-sensing dihydropyridine receptors (DHPR) in the T-tubule mechanically couple to ryanodine receptors (RyR1) on the sarcoplasmic reticulum, releasing stored Ca²⁺ into the cytosol.
Cytosolic Ca²⁺ binds troponin C , moving tropomyosin and exposing myosin-binding sites on actin. Cross-bridge cycling (ATP-dependent) shortens sarcomeres (sliding filament). Relaxation requires Ca²⁺ reuptake into the SR via SERCA , plus ACh hydrolysis by acetylcholinesterase in the cleft so the end plate can repolarize. Anything that reduces ACh release (LEMS, botulinum), blocks AChR (curare-like agents, MG antibodies), or prevents ACh breakdown (organophosphates) alters the safety factor of neuromuscular transmission.
- Step Key molecule / structure Failure mode example
- Presynaptic Ca²⁺ influx VGCC Lambert–Eaton
- ACh release SNARE-dependent vesicles Botulinum toxin
- End-plate depolarization Nicotinic AChR Myasthenia gravis; curare
- SR Ca²⁺ release DHPR–RyR1 Malignant hyperthermia (RyR1) conceptual
- Cross-bridge Actin–myosin + ATP ATP depletion (late rigor themes)
- Termination AChE; SERCA Organophosphate excess ACh
- Type I vs Type II Muscle Fibers
Type I (slow-twitch, oxidative): abundant mitochondria and myoglobin, rich capillary supply, fatigue-resistant—posture and endurance. Type II (fast-twitch): faster myosin ATPase; IIA has mixed oxidative-glycolytic capacity; IIX/IIB more glycolytic, powerful, fatigable—sprint/power tasks. Motor units are fiber-type homogeneous and recruited orderly (size principle: smaller slow units first). Denervation, training, and hormones remodel fiber properties; boards mainly require matching fiber type to metabolic profile and fatigue resistance.
- Fiber Speed Metabolism Fatigue Role
- Type I Slow Oxidative Resistant Endurance, posture
- Type IIA Fast Oxidative-glycolytic Intermediate Mixed activity
- Type IIX/IIB Fast Glycolytic Fatigable Power, sprint
- Duchenne and Becker Muscular Dystrophy
Dystrophin links the intracellular actin cytoskeleton to the transmembrane dystrophin-associated glycoprotein complex and extracellular matrix—stabilizing the sarcolemma during contraction. DMD gene on Xp21; X-linked inheritance.
Duchenne muscular dystrophy (DMD): usually frameshift/nonsense mutations → essentially absent dystrophin . Onset in early childhood: proximal weakness, Gowers sign, calf pseudohypertrophy (fat/fibrosis), elevated CK, wheelchair dependence in teens historically without modern care, cardiomyopathy and respiratory failure drive mortality. Female carriers may have mild weakness or elevated CK and cardiac risk.
Becker muscular dystrophy (BMD): typically in-frame mutations → reduced/truncated but partially functional dystrophin . Later onset, milder course, ambulatory longer; cardiomyopathy still important.
Both are dystrophinopathies; mutation reading-frame logic is the high-yield mechanistic discriminator.
Myotonic Dystrophy
Myotonic dystrophy type 1 (DM1): autosomal dominant CTG trinucleotide repeat expansion in DMPK (anticipation). Clinical: distal weakness, myotonia (delayed relaxation—grip myotonia, percussion myotonia), temporal wasting, cataracts, cardiac conduction block, hypogonadism, insulin resistance, frontal balding teaching habitus. Congenital DM1 with severe hypotonia can occur with large maternal expansions. Type 2 (DM2, CCTG in CNBP ) is milder/proximal-predominant—DM1 remains the classic board package.
Inflammatory Myopathies: Lab and Pattern Anchors
Revisited briefly from the rheumatology section with muscle-centric labs: polymyositis and dermatomyositis elevate CK (and aldolase, AST/ALT from muscle, LDH). ANA may be positive; anti-Jo-1 flags antisynthetase syndrome with ILD. Biopsy patterns (endomysial CD8 vs perimysial/complement capillary injury) separate PM vs DM. Inclusion body myositis (older adults, finger flexors/quadriceps, poor treatment response, rimmed vacuoles) is a common contrast case. Endocrine/toxic myopathies (hypothyroid, glucocorticoid, statin) enter the differential of proximal weakness with variable CK.
Myasthenia Gravis vs Lambert–Eaton
Myasthenia gravis (MG): autoimmune antibodies against postsynaptic nicotinic AChR (most common) or MuSK /LRP4 in subsets. Fewer functional receptors → smaller end-plate potentials → fatigable weakness. Pattern: ocular (ptosis, diplopia) often early; bulbar (dysarthria, dysphagia); limb fatigability; worse with repetition, better with rest. Thymoma/thymic hyperplasia associations are classic. Crisis can cause respiratory failure. Conceptual pharmacology: acetylcholinesterase inhibitors increase cleft ACh; crisis management distinguishes cholinergic vs myasthenic crisis clinically.
Lambert–Eaton myasthenic syndrome (LEMS): antibodies against presynaptic P/Q-type VGCC → impaired ACh release. Weakness often proximal legs; autonomic features (dry mouth); reflexes diminished but may improve after brief exercise; strength may improve temporarily with repeated use (facilitation)—opposite of MG fatigability teaching. Strong association with small cell lung cancer (paraneoplastic). Incremental response on high-rate repetitive nerve stimulation is the electrophysiologic teaching point (vs decremental in MG).
- Feature Myasthenia gravis Lambert–Eaton
- Target Postsynaptic AChR (or MuSK) Presynaptic VGCC
- ACh quanta Released normally; effect reduced Release reduced
- Fatigability Worsens with use May improve briefly with use
- Autonomic Usually not prominent Dry mouth common
- Cancer link Thymoma Small cell lung cancer
- RNS teaching Decremental Incremental (high rate)
- NMJ Toxins and Drugs: Botulinum, Curare, Organophosphates
Botulinum toxin cleaves SNARE proteins (serotype-specific targets such as SNAP-25 or synaptobrevin) → blocks ACh vesicle fusion → flaccid paralysis; also reduces autonomic cholinergic transmission (dry mouth, ileus themes). Used therapeutically in focal dystonia and cosmesis—mechanism remains SNARE cleavage.
Curare / nondepolarizing neuromuscular blockers (e.g., d-tubocurarine conceptual class) competitively antagonize nicotinic AChR → flaccid paralysis; overcome by increasing ACh (AChE inhibitors) in anesthesia teaching.
Depolarizing blocker succinylcholine activates then desensitizes AChR (phase concepts); contraindicated in certain hyperkalemia risk states—boards touch malignant hyperthermia risk with volatile anesthetics/succinylcholine in susceptible patients (RyR1).
Organophosphate / nerve gas AChE inhibition: excess ACh at muscarinic and nicotinic synapses → DUMBBELS/SLUDGE muscarinic picture plus fasciculations, weakness, and CNS effects. Treatment concepts: atropine (muscarinic), pralidoxime (regenerate AChE if timely), supportive care. Contrast with botulinum (too little ACh release) versus organophosphate (too much ACh signaling).
Demyelinating vs Axonal Neuropathy
Peripheral nerve disease localizes to axon, myelin, neuron cell body (neuronopathy), or vasa nervorum.
Demyelinating neuropathies: myelin injury slows conduction velocity, prolongs distal latencies, and may cause conduction block. Weakness and early areflexia are common; sensory large-fiber involvement causes paresthesias and proprioceptive loss. Examples: Guillain–Barré syndrome (AIDP form) , CIDP , some hereditary demyelinating neuropathies (CMT1).
Axonal neuropathies: axon loss reduces amplitude of action potentials with relatively preserved velocities until severe dropout. Length-dependent “stocking-glove” sensory patterns dominate many toxic-metabolic axonopathies (diabetes, alcohol, B12 deficiency—though B12 can be mixed). Wallerian degeneration distal to injury is the prototype axonal response.
- Feature Demyelinating Axonal
- Conduction velocity Markedly slowed Near normal until late
- SNAP/CMAP amplitudes May be relatively preserved early (or block) Reduced
- Reflexes Often lost early Variable
- Examples AIDP/GBS, CIDP, CMT1 Diabetic, toxic, CMT2
- Guillain–Barré vs CIDP
Guillain–Barré syndrome (GBS): acute monophasic polyradiculoneuropathy, often post-infection ( Campylobacter jejuni with molecular mimicry to gangliosides in AMAN/AMSAN variants; AIDP is demyelinating). Rapidly progressive ascending weakness, areflexia, cytoalbuminologic dissociation (high CSF protein, few cells), risk of respiratory failure and autonomic instability. IVIG/plasma exchange conceptual therapies; avoid equating with simple “peripheral neuropathy” without the acute areflexic pattern.
CIDP (chronic inflammatory demyelinating polyneuropathy): related immune-mediated demyelination but chronic (progression >8 weeks teaching threshold) or relapsing course; responds more often to corticosteroids (unlike typical GBS). Think of CIDP as the chronic cousin of AIDP.
Nerve Injury Classification Basics
Seddon/Sunderland teaching grades:
Neurapraxia: focal demyelination/conduction block without axonal interruption; good recovery weeks–months.
Axonotmesis: axon disrupted, connective tissue frameworks (endoneurium ± perineurium) partly preserved; Wallerian degeneration distal; regeneration ~1 mm/day if scaffolding intact.
Neurotmesis: full transection of axon and nerve sheaths; spontaneous recovery poor without surgical repair.
Clinically, closed stretch injuries may be neurapraxia/axonotmesis; open lacerations risk neurotmesis. Tinel sign and advancing sensory march can track regenerating axons.
Clinical Integration for NBME Vignettes
Map fatigable ocular-bulbar weakness to MG; proximal legs + dry mouth + cancer smoking history to LEMS; toddler Gowers + huge CK + X-linked family pattern to Duchenne; grip myotonia + cataracts + conduction block to myotonic dystrophy; post-diarrheal ascending areflexic paralysis to GBS; chronic demyelinating polyneuropathy to CIDP; hot swollen joint still belongs to the prior section—but toxin questions sit at the NMJ table (botulinum vs organophosphate opposite ACh tone). Fiber type and EC coupling supply the physiology base that makes each lesion’s weak link predictable.